Results 191 to 200 of about 12,467 (245)

Real-world population pharmacokinetics of tezacaftor-ivacaftor in children with cystic fibrosis: The SYM-CF study. [PDF]

Br J Clin Pharmacol
Vonk SEM, Terheggen-Lagro SWJ, Haarman EG, Janssens HM, Maitland-van der Zee AH, Kemper EM, Mathôt RAA, Amsterdam Mucociliary Clearance Disease (AMCD) research group.   +7 more
europepmc   +1 more source

Case Series on the Combined Therapy with Elexacaftor/Tezacaftor/Ivacaftor During Pregnancy in Women with Severe Cystic Fibrosis: A Retrospective Report from an Italian Centre. [PDF]

J Clin Med
Iacotucci P, Somma J, Ferrillo L, Celardo A, Conti V, Carlo CD, Rengo G, Corbi G, Carnovale V.   +8 more
europepmc   +1 more source

Understanding the action of bamocaftor as a potential drug candidate against Cystic Fibrosis Transmembrane Regulator protein: A computational approach. [PDF]

PLoS One
Patel N, Sarkar S, V M BM, Kashyap I, Thiruselvam P, Sundararajan V, Lulu Sudhakaran S.   +6 more
europepmc   +1 more source

Effects of CFTR Modulators on <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis. [PDF]

Infect Dis Rep
Pescaru CC, Crișan AF, Marițescu A, Cărunta V, Marc M, Dumitrache-Rujinski Ș, Laitin S, Oancea C.   +7 more
europepmc   +1 more source

Welsh, González, and Negulescu share Lasker Award recognizing transformative treatments for people with cystic fibrosis. [PDF]

J Clin Invest
Singer BD, Budinger GRS.
europepmc   +1 more source